European Patent Granted for ZUNVEYL in Alzheimer's, Extending IP Protection to 2042
ACOG sits 94% above its 52-week low of $4.5 on elevated volume (2.0× avg).
Summary
Alpha Cognition secured a European patent for the crystalline solid form of benzgalantamine, the active ingredient in its FDA-approved Alzheimer's drug ZUNVEYL. The grant covers pharmaceutical compositions, manufacturing methods, and medical uses, with potential protection through 2042 across key markets including the EU, UK, and Switzerland. This follows the June BEACON study results that showed strong real-world efficacy for ZUNVEYL, and recent insider buying by a 10% owner totaling over $2.5 million in two months. The patent solidifies the company's commercial moat in Europe, where Alzheimer's prevalence is high and no generic competition can emerge for over 15 years if validated in member states. With a market cap of just $183 million and a cash-burning profile, this IP milestone de-risks the long-term revenue stream and could attract partnership interest.
At the time of this announcement, ACOG was trading at $8.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $183.1M. The 52-week trading range was $4.50 to $10.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.